Freedom Broker Downgrades Sionna Therapeutics (SION) to Hold

Freedom Broker analyst Ilya Zubkov downgraded Sionna Therapeutics (NASDAQ: SION) from Buy to Hold, PT $38.00.

The analyst comments "The April 2026 completion of enrollment for the SION-719 Phase 2a trial eliminates timing uncertainty for a pivotal summer catalyst, but our Likelihood of Approval and target price remain unchanged until the upcoming readouts resolve the fundamental biological risk of the NBD1 stabilizer mechanism. ● Despite a 1Q’26 net loss of $26.8 million that exceeded Freedom Broker estimates due to R&D scaling, Sionna’s $289.9 million cash position provides a stable financial bridge into 2028 and the subsequent initiation of Phase 2b dose-ranging studies in the second half of 2026. ● We maintain our $38 target price and downgrade our rating from BUY to HOLD."

For an analyst ratings summary and ratings history on Sionna Therapeutics click here. For more ratings news on Sionna Therapeutics click here.

Shares of Sionna Therapeutics closed at $37.68 yesterday.

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• Freedom Broker Upgrades Serve Robotics (SERV) to Buy
• Intuitive Machines Inc. (LUNR) PT Lowered to $32 at Cantor Fitzgerald, Reaffirms Overweight Rating